Leukotrienes in gynaecology: the hypothetical value of anti-leukotriene therapy in dysmenorrhoea and endometriosis
review
OA: bronze
CC0
⤵ 18 in-corpus citations
AI-generated summary
Leukotrienes are present in the endometrium of women with dysmenorrhoea and elevated cytokines are found in endometriosis, suggesting a potential role for anti-leukotriene therapy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The lipoxygenase products (leukotrienes) have been demonstrated in many mammalian tissues including humans. They are widely distributed in the lungs, gut, uterus, kidneys, skin, heart and the liver. Their roles as mediators of inflammation have made them therapeutic targets. Significant amounts of leukotrienes have been demonstrated in the endometrium of women with primary dysmenorrhoea who do not respond to treatment with anti-prostaglandins. Also, in endometriosis, cytokines, which can initiate the cascade for the biosynthesis of leukotrienes, have been shown to be elevated. It is estimated that 10-30% of patients with painful periods fail to respond to prostaglandin (PG) synthetase inhibitors. Of adult females approximately 40% have painful menstruation and 10% of these are incapacitated for 1-3 days per month, and approximately 10% of women aged between 15-45 years suffer from endometriosis, which is a significant cause of infertility. Leukotriene receptor antagonists have recently been licensed for the treatment of asthma in the UK. In this review, we present the case for the potential use of these products in the management of primary dysmenorrhoea (especially in patients who are not responding to the traditional treatment using PG synthetase inhibitors) and possibly also in cases of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (74)
- 8 Prostaglandins, prostaglandin inhibitors and their roles in gynaecological disorders via openalex
- Endometriosis: Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection* via openalex
- Endometriosis: Soluble CD23 protein in the peritoneal fluid of patients with endometriosis via openalex
- Etiology and epidemiology of endometriosis via openalex
- Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. via openalex
- Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia via openalex
- Prevalence and genesis of endometriosis via openalex
- W1599947702 via openalex
- W1672565987 via openalex
- W1833164234 via openalex
- W1967314154 via openalex
- W1969632293 via openalex
- W1971569966 via openalex
- W1971697960 via openalex
- W1973712554 via openalex
- W1973832079 via openalex
- W1975790353 via openalex
- W1978646447 via openalex
- W1979224780 via openalex
- W1987288311 via openalex
- W1988188055 via openalex
- W1988387855 via openalex
- W1989733741 via openalex
- W1993513645 via openalex
- W1996400030 via openalex
- W2000098150 via openalex
- W2008334811 via openalex
- W2011793087 via openalex
- W2011964961 via openalex
- W2014768234 via openalex
- W2015808870 via openalex
- W2017162336 via openalex
- W2018499204 via openalex
- W2023140098 via openalex
- W2026310193 via openalex
- W2032830404 via openalex
- W2046679315 via openalex
- W2048521817 via openalex
- W2050252686 via openalex
- W2051958752 via openalex
- W2057160086 via openalex
- W2061588012 via openalex
- W2063153627 via openalex
- W2065283934 via openalex
- W2068503311 via openalex
- W2080764956 via openalex
- W2083057314 via openalex
- W2087019177 via openalex
- W2093691138 via openalex
- W2094395704 via openalex
- W2103847319 via openalex
- W2115903323 via openalex
- W2116594128 via openalex
- W2120253936 via openalex
- W2123773797 via openalex
- W2157948747 via openalex
- W2166525518 via openalex
- W2169850501 via openalex
- W2170973793 via openalex
- W2189668998 via openalex
- W2325612100 via openalex
- W2395627450 via openalex
- W2398955239 via openalex
- W2400136386 via openalex
- W2406954067 via openalex
- W2413992326 via openalex
- W76406945 via openalex
- W2416717033 via openalex
- W315764148 via openalex
- W1488413741 via openalex
- W1501551436 via openalex
- W1559121852 via openalex
- W1563821664 via openalex
- W1598413612 via openalex
Cited by (18)
- Comparison of the efficacy of dienogest and GnRH-a after endometriosis surgery 2023
- Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats? 2014
- Primary Dysmenorrhea: An Urgent Mandate 2013
- Possible involvement of nerve growth factor in dysmenorrhea and dyspareunia associated with endometriosis 2013
- Pentoxifylline for endometriosis 2012
- Medical Treatment in Endometriosis 2012
- Studying the Effect of Montelukast in the Treatment of Dysmenorrhea: A single-Blind, Placebo-controlled Trial 2012
- Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis 2009
- Pentoxifylline versus medical therapies for subfertile women with endometriosis 2009
- Pentoxifylline versus medical therapies for subfertile women with endometriosis 2009
- Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: A prospective, double-blind, randomized, placebo-controlled study 2009
- Dismenorreas 2008
- Oral eicosapentaenoic acid supplementation as possible therapy for endometriosis 2007
- Endometriosis: harmful survival of an ectopic tissue 2006
- Primary dysmenorrhoea 2006
- Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? 2003
- Medical Management of Endometriosis: Novel Targets and Approaches towards the Development of Future Treatment Regimes 2003
- Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? 2003
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:13:41.710148+00:00
License: CC0
· commercial use OK